VITHYA LAKSHMI

NPM 260110142018

JOURNAL REVIEW

ROLE OF ENGRAILED-2 (EN2) AS A PROSTATE CANCER DETECTION BIOMARKER IN

GENETICALLY HIGH RISK MEN

The aim of this study was to assess the potential of EN2 urine for early diagnosis of Prostate
Cancer in the IMPACT study population. Based on the review journal it has been made that the
EN2 pee biomarker can identify individuals with clinically relevant prostate cancer. BRCA1 and
BRCA2 male mutation attackers are at high risk of developing prostate cancer significantly and
can benefit from screening. Urine samples from BRCA1 and BRCA2 mutation carriers were
evaluated. Based on EN2 screening results found EN2 levels were significantly higher in those
diagnosed with cancer compared with those who did not have a cancer diagnosis, p 0.001.
Subjects underwent annual PSA screening with diagnostic biopsy triggered by PSA> 3.0 ng / ml.
The EN2 level of urine was measured by ELISA and had a sensitivity of 66.7% and a specificity
of 89.3% for cancer detection. There was no statistically significant difference in EN 2 levels by
genetic status or Gleason score. EN2 urine is useful as a non-invasive early biomarker for the
detection of prostate cancer in genetically high-risk individuals.

From journal data it can be discussed that EN2 represents potentially attractive biomarkers for
early detection of cancer. Urine-based test is stable for 4 days at room temperature, suitable for
collection of post samples. Unlike some other urinary markers such as PCA3 and TMPRSS2-
ERG, prior DRE is not required to improve the ability of acceptability to individuals and reduce
costs. Current lateral current strips in commercial development will increase the speed and ease
of investigation of EN2 as a starting point of early cancer detection markers. The IMPACT study
is expected to complete the recruitment of operators and controls BRCA1 and BRCA2. It is
expected to provide further information on the usefulness of PSA screening in this high risk
group and also provide a useful sample bank for EN2 investigations and new detection or
prognostic biomarkers for PCs. As more recruits reach the point of 5 years when an optional
prostate biopsy is offered regardless of the PSA information that will further be available
regarding the true cancer status of these individuals and the effectiveness of EN2 as the initial
biomarker for PCs.

REFERENCE

Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in

genetically high risk men

Emma Killick, Richard Morgan, Francesca Launchbury, Elizabeth Bancroft, Elizabeth Page,
Elena Castro, Zsofia Kote-Jarai, Armen Aprikian, Ignacio Blanco, Virginia Clowes, Susan
Domchek, Fiona Douglas, Diana Eccles, D. Gareth Evans, Marion Harris, Judy Kirk, Jimmy
Lam, Geoffrey Lindeman, Gillian Mitchell, Nicholas Pachter, Christina Selkirk, Kathy Tucker,
Janaz Zgajnar, Rosalind Eeles, Hardev Pandha
Sci Rep. 2013; 3: 2059. Published online 2013 Jun 24. doi: 10.1038/srep02059

PMCID: PMC3690389